Literature DB >> 28662308

Gender disparity in fistula use at initiation of hemodialysis varies markedly across ESRD networks-Analysis of USRDS data.

Mariana Markell1, Amarpali Brar1, Dimitre G Stefanov2, Moro O Salifu1.   

Abstract

BACKGROUND: Gender disparities had been noted in the care of women with end stage renal disease (ESRD) in the early 2000's, including less frequent initiation of hemodialysis utilizing a fistula but more recent data have not been examined and underlying factors have not been extensively studied. STUDY
DESIGN: Data from the United States Renal Data System (USRDS) were examined, including 202,999 hemodialysis patients. Only those who had received prior nephrology care were included. Multiple logistic regression was used, adjusted for possible confounders, including age, race, cause of ESRD, BMI, height, history of alcohol or drug abuse, medical comorbidities, ability to ambulate, time of nephrology care, type of insurance, and ESRD network.
RESULTS: The odds of arteriovenous fistula (AVF) use at initiation of hemodialysis were significantly lower in women compared to men (OR = 0.69, 95% CI 0.67-0.71, P < 0.0001). The gender gap in AVF use at initiation was highest in New York and the upper Midwest (networks 2 and12) and smallest for Southern California and the Pacific Northwest and Alaska (18 and 16). Gender disparity was more pronounced for black women, with odds ratios for AVF use at initiation of dialysis (OR = 0.66, 95% CI 0.62-0.69), P < 0.0001 as compared to non-black (OR 0.70, 95% CI 0.68-0.73), P ≤ 0.0001. LIMITATIONS: Limitations include use of USRDS data. Data misclassification or errors in data reporting may exist and certain comorbid conditions may be underreported. Data regarding rate of primary fistula non-function are also not available.
CONCLUSION: Adjusted odds ratio for AVF use was significantly lower in women compared to men, independent of time of nephrology care and other predictors. The gender disparity was most pronounced for black women and also varied from 20% to 46% lower odds for AVF use in women for different ESRD networks, after controlling for possible confounding variables, suggesting that practice based factors may be of importance in explaining this important finding.
© 2017 International Society for Hemodialysis.

Entities:  

Keywords:  AVF; ESRD network; dialysis; gender disparity

Mesh:

Year:  2017        PMID: 28662308     DOI: 10.1111/hdi.12579

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  5 in total

1.  Gender Disparities in Vascular Access Surgical Outcomes in Elderly Hemodialysis Patients.

Authors:  Timmy Lee; Joyce Qian; Mae Thamer; Michael Allon
Journal:  Am J Nephrol       Date:  2018-12-13       Impact factor: 3.754

Review 2.  Perspectives in Individualizing Solutions for Dialysis Access.

Authors:  Silvi Shah; Micah R Chan; Timmy Lee
Journal:  Adv Chronic Kidney Dis       Date:  2020-05       Impact factor: 3.620

3.  Racial and Sex Disparities in Catheter Use and Dialysis Access in the United States Medicare Population.

Authors:  Shipra Arya; Taylor A Melanson; Elizabeth L George; Kara A Rothenberg; Manjula Kurella Tamura; Rachel E Patzer; Jason M Hockenberry
Journal:  J Am Soc Nephrol       Date:  2020-01-15       Impact factor: 10.121

4.  Gender and Racial Disparities in Initial Hemodialysis Access and Outcomes in Incident End-Stage Renal Disease Patients.

Authors:  Silvi Shah; Anthony C Leonard; Karthikeyan Meganathan; Annette L Christianson; Charuhas V Thakar
Journal:  Am J Nephrol       Date:  2018-07-10       Impact factor: 3.754

Review 5.  Sex and gender: modifiers of health, disease, and medicine.

Authors:  Franck Mauvais-Jarvis; Noel Bairey Merz; Peter J Barnes; Roberta D Brinton; Juan-Jesus Carrero; Dawn L DeMeo; Geert J De Vries; C Neill Epperson; Ramaswamy Govindan; Sabra L Klein; Amedeo Lonardo; Pauline M Maki; Louise D McCullough; Vera Regitz-Zagrosek; Judith G Regensteiner; Joshua B Rubin; Kathryn Sandberg; Ayako Suzuki
Journal:  Lancet       Date:  2020-08-22       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.